Sign in
IGC Stock Price, Chart, Stats & News
IGC Pharma, Inc.
Save
IGC Pharma, Inc. (IGC) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
IGC chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 33.44% |
Operating margin | -763.72% |
Pretax margin | -445.62% |
Net margin | -445.62% |
Effective tax rate | – |
ROA | -55.01% |
ROE | -76.54% |
D/E | 0.02x |
Interest coverage ratio | – |
IGC valuation
P/E | – |
P/S | 21.04x |
P/B | 3.27x |
P/CF | -4.45x |
P/FCF | -4.36x |
P/OCF | -4.45x |
PEG | -0.22x |
EV multiple | -3.42x |
About
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research.
Similar securities
Based on sector and market capitalization
Report issue